$283 Million is the total value of Pivotal bioVenture Partners Investment Advisor LLC's 9 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | RALLYBIO CORP | $39,930,000 | – | 2,271,311 | +100.0% | 14.11% | – | |
FUSN | Buy | FUSION PHARMACEUTICALS INC | $12,659,000 | +0.4% | 1,598,379 | +0.0% | 4.47% | -10.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
KARUNA THERAPEUTICS INC | 12 | Q3 2023 | 65.4% |
VAXCYTE INC | 12 | Q3 2023 | 19.5% |
INOZYME PHARMA INC | 12 | Q3 2023 | 10.8% |
ARCUTIS BIOTHERAPEUTICS INC | 12 | Q3 2023 | 6.2% |
FUSION PHARMACEUTICALS INC | 12 | Q3 2023 | 6.2% |
ALIGOS THERAPEUTICS INC | 12 | Q3 2023 | 8.0% |
BOLT BIOTHERAPEUTICS INC | 11 | Q3 2023 | 20.0% |
RALLYBIO CORP | 9 | Q3 2023 | 14.1% |
AKOUOS INC | 8 | Q3 2022 | 11.7% |
EXSCIENTIA PLC | 8 | Q3 2023 | 6.4% |
View Pivotal bioVenture Partners Investment Advisor LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-14 |
13F-HR | 2024-02-13 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-12 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-10 |
13F-HR | 2022-08-12 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-14 |
View Pivotal bioVenture Partners Investment Advisor LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.